Sanford Guide to HIV/AIDSTherapy 23/e 2015

The Sanford Guide to HIV/AIDS Therapy

The Sanford Guide to HIV/AIDS and Viral Hepatitis Therapy is in its 22nd edition in print for 2014. This edition reflects the continuing evolution of HIV to a manageable chronic disease, at least in parts of the world with access to the latest antiretroviral drugs. New agents, new once-daily combination ARV drug formulations and new guidelines on pre-exposure prophylaxis (PrEP) are included. ART recommendations have been updated in accordance with the most recent sets of guidelines and the section on HIV diagnostics has been revised to include newly available tests. We have done a major revision of complications of ART, AIDS-related complications, and opportunistic infections to reflect the changing understanding and management of HIV.

We have significantly expanded our coverage of diagnosis and treatment of Hepatitis B and Hepatitis C virus infections. In many ways, the rapid development of novel treatments of HCV mimic remarkably the explosion of new drugs for HIV that emerged in the mid-1990s, constituting the HAART revolution. For the first time in over 20 years, outside of the release of pegylated interferon, completely new drugs are approved for use in patients with HCV infection. These new direct acting agents have improved the sustained virologic response (SVR), or cure, rate for HCV genotype 1 infections to levels unimaginable just 5 years ago. What’s more, there are over 30 other new anti-HCV specific drugs in development that will further revolutionize the treatment of HCV over the next decade. This edition of the Guide provides an updated listing of these new agents in development.